Silence Therapeutics plc (NASDAQ:SLN) Receives Average Rating of “Buy” from Brokerages

Silence Therapeutics plc (NASDAQ:SLN) has received a consensus rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $57.20.

Several equities research analysts have weighed in on SLN shares. HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Monday, December 9th. Morgan Stanley reissued an “overweight” rating and set a $49.00 target price on shares of Silence Therapeutics in a research report on Tuesday, October 8th. Jefferies Financial Group began coverage on shares of Silence Therapeutics in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price target for the company. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a report on Monday, December 2nd.

Institutional Trading of Silence Therapeutics

A number of institutional investors have recently made changes to their positions in SLN. Values First Advisors Inc. purchased a new position in shares of Silence Therapeutics in the 3rd quarter valued at approximately $56,000. Quarry LP purchased a new position in shares of Silence Therapeutics in the second quarter worth $114,000. Verition Fund Management LLC acquired a new stake in shares of Silence Therapeutics during the third quarter worth $207,000. Custom Index Systems LLC purchased a new stake in shares of Silence Therapeutics during the second quarter valued at $282,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Silence Therapeutics during the third quarter valued at $318,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Stock Performance

Shares of NASDAQ SLN opened at $6.33 on Friday. Silence Therapeutics has a 52-week low of $5.81 and a 52-week high of $27.72. The firm has a market capitalization of $189.44 million, a price-to-earnings ratio of -4.03 and a beta of 1.05. The stock has a 50 day moving average price of $12.93 and a 200 day moving average price of $16.79.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.